ALLMedicine™ Leukemia Center
Research & Reviews 13,619 results
https://doi.org/10.1080/10428194.2022.2090549
Leukemia & Lymphoma; Xu Z, Yin J et. al.
Jun 28th, 2022 - This study aims to evaluate the possibility of tyrosine kinase inhibitors (TKIs) discontinuation in chronic myeloid leukemia (CML) patients who obtained sustained deep molecular response (DMR) and to explore the prognostic role of NK cells in trea...
https://doi.org/10.1038/s41375-022-01629-7 10.2217/fon-2017-0442 10.1182/asheducation-2013.1.138 10.1038/s41375-018-0313-8 10.1182/blood-2017-09-806398 10.1056/NEJMoa1509388 10.1182/blood-2014-10-606038 10.1056/NEJMoa1815281 10.1056/NEJMoa1713976 10.1016/S1470-2045(18)30788-5
Leukemia von Tresckow J, Cramer P et. al.
Jun 26th, 2022 - Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial.|2022|von Tresckow J,Cramer P,Robrecht S,Langerbeins P,Fink AM,|
https://doi.org/10.1038/s41409-022-01674-x 10.1182/blood.V89.12.4531 10.3324/haematol.2014.113571 10.1200/JCO.2015.62.7273 10.1016/j.bbmt.2008.03.005 10.1182/blood-2015-04-639831 10.2991/chi.d.200405.001 10.1111/bjh.13923 10.1182/blood-2011-03-344853 10.1182/blood-2015-01-623991 10.1038/bmt.2013.166 10.1016/j.bbmt.2014.08.013 10.1016/j.bbmt.2015.04.025 10.1016/j.bbmt.2018.01.031 10.1038/bmt.2016.239 10.1097/00007890-197410000-00001 10.1016/0002-9343(80)90380-0 10.1038/bmt.2015.305 10.1080/01621459.1958.10501452 10.2307/2530374 10.2991/chi.d.191207.001 10.1182/blood-2016-08-733196 10.1200/JCO.2008.20.9692 10.1038/sj.leu.2404037 10.1016/S2352-3026(18)30022-X 10.1186/s13045-016-0248-3 10.1182/bloodadvances.2019000627 10.1002/cncr.31941 10.3324/haematol.2020.268839 10.1038/sj.leu.2403967 10.1016/j.bbmt.2009.07.004 10.1038/s41409-020-0803-y 10.1002/cncr.27786 10.1038/sj.bmt.1705863 10.1016/j.bbmt.2019.12.725 10.1016/j.bbmt.2019.05.014 10.1038/s41409-020-01074-z 10.2991/chi.k.210731.001
Bone Marrow Transplantation; Devillier R, Galimard JE et. al.
Jun 26th, 2022 - The optimal conditioning regimen prior haploidentical stem cell transplantation (Haplo-SCT) with post transplantation cyclophosphamide (PT-Cy) for acute myeloid leukemia (AML) remains unknown. A non-myeloablative conditioning (NMAC) regimen (cyclo...
https://doi.org/10.1007/s00280-022-04448-w 10.1038/sj.leu.2404593 10.1016/s1535-6108(02)00069-7 10.1080/13543784.2017.1275564 10.1056/NEJMoa1614359 10.1056/NEJMoa1513098 10.1086/649879 10.1093/jac/dkt329 10.1007/s00277-020-04107-1 10.1111/imj.12595 10.1007/s00277-017-3196-2 10.1093/cid/ciw326 10.1093/jac/dky286 10.1200/JCO.18.00374 10.1111/bcp.12496 10.1124/dmd.116.072744 10.1124/dmd.117.078006 10.1021/acs.biochem.8b00727 10.1200/JCO.2001.19.5.1485 10.1124/dmd.31.7.815 10.1007/s00280-013-2287-6 10.1056/NEJMoa061094
Cancer Chemotherapy and Pharmacology; Sechaud R, Sinclair K et. al.
Jun 26th, 2022 - Midostaurin, approved for the treatment of newly diagnosed, FLT3-mutated acute myeloid leukemia (AML), is metabolized by cytochrome P450 3A4 (CYP3A4). Midostaurin with concomitant strong CYP3A4 inhibitors use (e.g., antifungal azoles) may result i...
https://doi.org/10.1002/ajh.26642
American Journal of Hematology; Jabbour E, Kantarjian H
Jun 26th, 2022 - Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm with an incidence of 1-2 cases per 100,000 adults. It accounts for approximately 15% of newly diagnosed cases of leukemia in adults DIAGNOSIS: CML is characterized by a balanced genet...
Guidelines 15 results
https://doi.org/10.6004/jnccn.2021.0002
Journal of the National Comprehensive Cancer Network : JN... Pollyea DA, Bixby D et. al.
Jan 7th, 2021 - The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regard...
https://doi.org/10.6004/jnccn.2020.0047
Journal of the National Comprehensive Cancer Network : JN... Deininger MW, Shah NP et. al.
Oct 7th, 2020 - Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phas...
https://doi.org/10.1016/j.bbmt.2020.09.020
Biology of Blood and Marrow Transplantation : Journal of ... Dholaria B, Savani BN et. al.
Sep 24th, 2020 - The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence-based review. An AML expert panel, consisting of both transplant and...
https://doi.org/10.6004/jnccn.2020.0006
Journal of the National Comprehensive Cancer Network : JN... Wierda WG, Byrd JC et. al.
Feb 6th, 2020 - Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are characterized by a progressive accumulation of leukemic cells in the peripheral blood, bone marrow, and lymphoid tissues. Treatment of CLL/SLL has evolved significantly in...
https://doi.org/10.6004/jnccn.2020.0001
Journal of the National Comprehensive Cancer Network : JN... Brown P, Inaba H et. al.
Jan 8th, 2020 - Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved su...
Drugs 201 results see all →
News 632 results
https://www.medscape.com/viewarticle/976065
Jun 23rd, 2022 - The study was published on researchsquare.com as a preprint and has not yet been peer reviewed. Key Takeaway Regarding consolidation therapy for younger patients with acute myeloid leukemia (AML), there was no survival benefit from taking high-dos...
https://www.medscape.com/viewarticle/975652
Jun 15th, 2022 - Use of the targeted therapy combination of venetoclax plus obinutuzumab for fit patients with chronic lymphocytic leukemia (CLL) significantly improved progression-free survival (PFS) at 3 years compared with standard chemoimmunotherapy, new phase...
https://www.medscape.com/viewarticle/975457
Jun 13th, 2022 - The potent oral FLT3 inhibitor quizartinib more than doubled overall survival among patients newly diagnosed with FLT3-ITD-positive acute myeloid leukemia (AML) compared with standard chemotherapy, new phase 3 data show. Among adults who received ...
https://www.medscape.com/viewarticle/975438
Jun 12th, 2022 - Older, fit patients with acute myeloid leukemia (AML) pretreated with a 10-day regimen of decitabine (Dacogen) prior to allogeneic hematopoietic stem cell transplantation had similar overall survival compared with those receiving conventional inte...
https://www.medscape.com/viewarticle/964532
May 19th, 2022 - This transcript has been edited for clarity. Gail J. Roboz, MD: Hi, everyone. My name is Dr Gail Roboz. I'm a professor of medicine and director of the leukemia program at Weill Cornell Medicine and the NewYork-Presbyterian Hospital in New York Ci...
